Home | Investors | ASX Announcements | 2016 ASX Announcements 2016 Date Document 23/12/2016 Customer Newsletter December 2016 15/12/2016 FerriScan use showcased at ASH conference 01/12/2016 Equity Research Report Released 28/11/2016 Initial Director's Interest Notice 24/11/2016 Results of Meeting 24/11/2016 Annual General Meeting Presentation 16/11/2016 Director Appointment 10/11/2016 Results Recommending Use of FerriScan in Sickle Cell Disease 09/11/2016 Change in substantial holding 28/10/2016 Appendix 4C - quarterly 24/10/2016 Notice of Annual General Meeting/Proxy Form 24/10/2016 Annual Report to shareholders 13/10/2016 Resonance Health commences involvement in diabetes study 30/09/2016 Customer Newsletter 29/09/2016 Appendix 4G 29/09/2016 Full Year Statutory Accounts 23/09/2016 Bone Marrow Iron - Regulatory Submission 13/09/2016 Becoming a substantial holder 07/09/2016 Expansion of Involvement in Pharmaceutical Clinical Trial 31/08/2016 Appendix 3B Issue of Employee Shares 30/08/2016 Preliminary Final Report 11/08/2016 Correction of Link - HepaFat-Scan International Publication 11/08/2016 HepaFat-Scan International Scientific Journal 26/07/2016 Appendix 4C - quarterly 29/06/2016 Customer News letter 29/06/2016 Appendix 3B 14/06/2016 Operational Update 30/05/2016 New UK Standards recommend FerriScan 29/04/2016 Appendix 4C Quarterly Cashflow Report 20/04/2016 Completion Minimum Holding Share Sale 05/04/2016 Second and Final Notice - Minimum Holding Share Sale 31/03/2016 Newsletter 25/02/2016 Half Year Accounts 23/02/2016 Minimum Holding Share Sale 01/02/2016 Appendix 4C - quarterly
